Sponsored by
This is an important trial. In the phase 2 trial, on newly diagnosed GBM patients who only had biopsies - not subtotal resection or complete resection, they had "in patients with inoperable tumors, who demonstrated a 380 percent increase in survival at two years."
This is so important that I am including it in my presentation to the FDA next week as an example of a drug that needs to be approved quickly!